Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMO-103 in Pancreatic Ductal Adenocarcinoma
NCT07089940Phase 1Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OMO-103 in pancreatic ductal adenocarcinoma (PDAC), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Measurable change in tumor biology. Started Jan 2026; status: recruiting.
02
Drugs
OMO-103
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07089940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089940.